Acumen Pharmaceuticals, Inc (ABOS)
3.18
+0.09 (2.91%)
Upcoming Events
Latest Headlines
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
September 2, 2026 4:00 PM - StreetInsider
Form S-8 Acumen Pharmaceuticals,
August 12, 2026 4:24 PM - SEC Filing
Form 10-Q Acumen Pharmaceuticals, For: Jun 30
August 12, 2026 4:14 PM - SEC Filing
Acumen Pharmaceuticals, Inc. (ABOS) Misses Q2 EPS by 9c
August 12, 2026 7:44 AM - StreetInsider
Form 8-K Acumen Pharmaceuticals, For: Aug 12
August 12, 2026 7:03 AM - SEC Filing
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
August 12, 2026 7:00 AM - StreetInsider
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
August 5, 2026 4:00 PM - StreetInsider
Acumen Pharmaceuticals shares brain delivery antibody data at AAIC 2026
July 15, 2026 7:31 AM - StreetInsider
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
July 15, 2026 7:30 AM - StreetInsider
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 202
July 7, 2026 7:30 AM - StreetInsider
Form 4 Acumen Pharmaceuticals, For: Jun 15 Filed by: Porter Derrell
June 17, 2026 5:10 PM - SEC Filing
Form 144 Acumen Pharmaceuticals, Filed by: Porter Derrell
June 17, 2026 4:02 PM - SEC Filing
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform
June 17, 2026 12:30 PM - BizWire
Form 144 Acumen Pharmaceuticals, Filed by: Porter Derrell
June 16, 2026 5:04 PM - SEC Filing
Form 8-K Acumen Pharmaceuticals, For: Jun 12
June 16, 2026 7:34 AM - SEC Filing
ACUMEN Pharmaceuticals nominates two Alzheimer's drug candidates
June 16, 2026 7:32 AM - StreetInsider
Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease
June 16, 2026 7:30 AM - StreetInsider
Form 144 Acumen Pharmaceuticals, Filed by: Porter Derrell
June 15, 2026 6:32 PM - SEC Filing
Form 4 Acumen Pharmaceuticals, For: Jun 09 Filed by: Fountain Nathan B
June 10, 2026 4:51 PM - SEC Filing
Form 144 Acumen Pharmaceuticals, Filed by: Fountain Nathan B
June 9, 2026 4:16 PM - SEC Filing
Full Article List
